KK3A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Revenue GrowthSustained ~90% gross margins with ~20% TTM revenue growth indicate attractive unit economics for Cytokinetics’ therapeutics and improving commercial/partner momentum. These structural margins provide a durable lever: as volumes scale, high gross margins can translate into outsized incremental profitability if operating spend stabilizes.
Validated Commercial Launch And Early AdoptionFirst commercial sales and rapid prescriber uptake (hundreds of HCPs, quick conversion to paid prescriptions, broad REMS certifications) materially de‑risk the company’s transition from development to commercialization. Durable prescriber engagement and early real‑world use provide a foundation for repeatable revenue growth as access and coverage expand.
Material Capital Raise And Solid Cash RunwayThe $760M offering combined with a ~ $1.1B cash position meaningfully extends operating runway, enabling launches, regulatory filings and late‑stage trials without immediate dilutive stress. This strengthened liquidity supports multi‑quarter execution of commercial expansion and pipeline milestones, reducing near‑term refinancing risk.
Bears Say
Deep Ongoing Losses And Stressed Balance SheetCytokinetics is still deeply unprofitable with substantial negative operating cash flow and large cumulative losses. Negative stockholders’ equity and roughly $1.04B of debt constrain financial flexibility, increasing the probability of further dilution or costly refinancing if commercial cash flows do not scale as expected.
Very High Ongoing Operating SpendLaunch and commercialization materially increased SG&A and combined R&D/SG&A guidance remains very high. Persistently elevated operating expenses will pressure margins and require either sustained, rapid top‑line growth or continued external financing, making long‑term profitability contingent on successful scale‑up of product sales.
Safety Signals In Pivotal Acacia HCM TrialObserved declines in LVEF and a small number of serious heart‑failure events create enduring regulatory and prescriber risk. Such safety findings can limit label scope, slow physician uptake, and trigger additional monitoring or restrictions that diminish market penetration even after approvals, affecting long‑term commercial potential.
Cytokinetics News
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
Currently, no data Available
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is CHF8.54B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on May 05, 2026. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$1.335 by -$0.015.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.32.
How many shares outstanding does Cytokinetics have?
Currently, no data Available
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.35 in its last earnings report, missing expectations of -$1.335. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CH:KK3A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF86.66 (― Downside)
CHF86.66 (― Downside)
Insider Transactions
Sold Shares
Worth CHF15.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.94%
12-Months-Change
Fundamentals
Return on Equity
139.66%
Trailing 12-Months
Asset Growth
0.75%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
KK3A Company Deck
KK3A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple major positive developments: first commercial launch with encouraging early uptake and revenue, EU approval and imminent German launch, positive pivotal Acacia HCM topline results that could expand aficamtin to nonobstructive HCM, and continued pipeline progress and regulatory filings. Offsetting these positives are meaningful launch and operating costs (SG&A up sharply), continued cash burn, incomplete payer access early in launch, and notable safety observations in Acacia HCM (higher incidence of LVEF decline and a small number of serious heart failure events) that will require regulatory and prescriber scrutiny. On balance, the transformative commercial and clinical milestones materially outweigh the near-term financial and safety challenges described on the call.View all CH:KK3A earnings summariesKK3A Stock 12 Month Forecast
Average Price Target
$86.66
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Options Prices
Currently, No data available
---